HRP970387A2 - Isobutylgaba and its derivatives for the treatment of pain - Google Patents
Isobutylgaba and its derivatives for the treatment of painInfo
- Publication number
- HRP970387A2 HRP970387A2 HR60/022,337A HRP970387A HRP970387A2 HR P970387 A2 HRP970387 A2 HR P970387A2 HR P970387 A HRP970387 A HR P970387A HR P970387 A2 HRP970387 A2 HR P970387A2
- Authority
- HR
- Croatia
- Prior art keywords
- treated
- pain
- animals
- gabapentin
- isobutylgaba
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims description 28
- 230000036407 pain Effects 0.000 title claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 26
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 15
- 208000004550 Postoperative Pain Diseases 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 208000004296 neuralgia Diseases 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 208000021722 neuropathic pain Diseases 0.000 claims description 5
- AYXYPKUFHZROOJ-UHFFFAOYSA-N 3-(azaniumylmethyl)-5-methylhexanoate Chemical compound CC(C)CC(CN)CC(O)=O AYXYPKUFHZROOJ-UHFFFAOYSA-N 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 208000001387 Causalgia Diseases 0.000 claims description 3
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 3
- 208000004983 Phantom Limb Diseases 0.000 claims description 3
- 206010056238 Phantom pain Diseases 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 58
- 208000004454 Hyperalgesia Diseases 0.000 description 58
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 31
- 229960002870 gabapentin Drugs 0.000 description 29
- 210000002683 foot Anatomy 0.000 description 23
- 238000001356 surgical procedure Methods 0.000 description 22
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 241000700159 Rattus Species 0.000 description 16
- 229960005181 morphine Drugs 0.000 description 16
- 239000000679 carrageenan Substances 0.000 description 13
- 229920001525 carrageenan Polymers 0.000 description 13
- 229940113118 carrageenan Drugs 0.000 description 13
- 235000010418 carrageenan Nutrition 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 13
- 230000003447 ipsilateral effect Effects 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000000692 Student's t-test Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000003040 nociceptive effect Effects 0.000 description 8
- 238000012353 t test Methods 0.000 description 8
- 208000035154 Hyperesthesia Diseases 0.000 description 7
- 210000000548 hind-foot Anatomy 0.000 description 6
- 238000000540 analysis of variance Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 206010053552 allodynia Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 244000144993 groups of animals Species 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 201000005518 mononeuropathy Diseases 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- HGINADPHJQTSKN-UHFFFAOYSA-M 3-ethoxy-3-oxopropanoate Chemical compound CCOC(=O)CC([O-])=O HGINADPHJQTSKN-UHFFFAOYSA-M 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000006000 Knoevenagel condensation reaction Methods 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010068106 Occipital neuralgia Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- -1 aliphatic nitro compounds Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 108010056028 auromycin Proteins 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000003461 brachial plexus Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- MNBODUCODDEXEE-UHFFFAOYSA-N ethyl 4,4-dimethylpent-2-enoate Chemical compound CCOC(=O)C=CC(C)(C)C MNBODUCODDEXEE-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000917 hyperalgesic effect Effects 0.000 description 1
- 208000021731 hypoalgesia Diseases 0.000 description 1
- 230000036032 hypoalgesia Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- OBLVSONFNRLRIQ-UHFFFAOYSA-N lithium;ethyl acetate Chemical compound [Li+].CCOC([CH2-])=O OBLVSONFNRLRIQ-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- KPSSIOMAKSHJJG-UHFFFAOYSA-N neopentyl alcohol Chemical compound CC(C)(C)CO KPSSIOMAKSHJJG-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Description
Dosadašnje spoznaje
U ovom izumu korišteni su analozi glutaminske kiseline i γ-aminomaslačne kiseline 8GABA) za terapiju boli, jer ti spojevi djeluju kao analgetici i antihiperalergici. Prednost korištenja ovih spojeva je u tome što njihova ponovljena upotreba ne dovodi do tolerancije niti do efekta unakrsne tolerancije između morfina i ovih spojeva.
Spojevi iz izuma poznata su sredstva u terapiji napada uzrokovanog poremećajem nervnog sustava kao što je epilepsija, Huntingtonova koreja, cerebralna ishemija, Parkinsonova bolest, tardivna diskinezija i spastičnost. Također je predloženo da se spojevi mogu koristiti kao antidepresivna, anskiolitilka i antipsihotička sredstva. Vidi WO 92/09560 (patent Sjedinjenih Država br. 618,692 od 27. studenog 1990) i WP 93/23383 (patent Sjedinjenih Država br. 886,080 od 20. svibnja 1992).
Sažetak izuma
Ovaj izum prikazuje metodu korištenja spojeva formule I u tretmanu bolova, posebice u tretmanu kroničnih bolnih poremećaja. Takvi poremećaji uključuju, ali nisu njih ograničeni, bol uzrokovanu upalom, postoperativnu bol, bol uzrokovanu osteoartritisom koji je povezan s karcinomom u metastazi, neuralgiju trigeminusa, akutnu herpesom i postherpesom povezanu neuralgiju, dijabetičnu neuropatiju, kausalgiju, avulziju brahinalnog pleksusa, okcipatalnu neuralgiju, refleksnu simpatitičku distrofiju, fibromialgiju, giht, fantomsku bol udova, bol od opeklina i ostale oblike neuralgičnih neuropatilnih i izopatičnih sindroma.
Spoj formule I
[image]
ili je odgovarajuća farmaceutski prihvatljiva sol, pri čemu
R1 je ravni ili razgranati alkil od 1 do 6 atoma ugljika, fenil ili cikloalkil od 3 do 6 atoma ugljika,
R2 je vodik ili metil, te
R3 je vodik, metil ili karboksil.
Dijastereomeri i enantiomeri spojeva I su uključeni u izum.
Preferirani spojevi u izumu jesu prema patentnom zahtjevu 1 oni kod kojih R2 i R3 jesu vodici, a R1 je -(CH2)0-2- i C4H9 u obliku (R), (S) ili (R,S) izomera.
Još preferiraniji spojevi u izumu su (S)-3-(aminometil)-5-metilheksanska kiselina i 3-aminometil-5-metil-heksanska kiselina.
Kratak opis slika
Slika 1 Učinak gabapentina (1-(aminometil)-cikloheksanoctene kiseline), CI-1008 ((S)-3-(aminometil)-5-metilheksanske kiseline) i 3-aminometil-5-heksanske kiseline formalinskom testu na šape štakora
Testirani spojevi su davani s.c. jedan sat prije intraplantarne injekcije 50 µl formalina. Vrijeme provedeno u lizanju/grickanju šape tijekom ranih i kasnih faza je bilježeno. Rezultati su prikazani kao srednja vriejdnost ± standardna devijacija (engl SEM) od 6 do 8 životinja po skupini *P<0.05 i **P<0.01 znatno se razlikuju za kontrolnu skupinu tretiranu vehikulima (Veh. (ANOVA nakon čega slijedi Dunnetov t-test).
Slika 2 Učinak gabapentina u CI-1008 na karagenom izazvanu mehaničku hiperalgeziju
Nociceptivni prag osjetljivosti na pritisak je mjeren kod štakora korištenjem testa pritiskanja šape, Određivanje bazne linije (BL) je provedeno na životinjama prije davanja 100 µ 2% karagena intaplantarnom injekcijom. Rezultati su prikazani kao srednja vrijednost (±SEM) od 8 životinja po skupini. Gabapentin (GP), CI-1008 ili morfin (MOR; 3 mg/kg) je davan s.c. 3.5 sata nakon *P<0.05 i **P<0.01 znatno se razlikuju za kontrolnu skupinu tretiranu u vehikulima (Veh.) (ANOVA nakon čega slijedi Dunnetov t-test).
Slika 3. Učinak gabapentina i CI-1008 na karagenom izazvanu termičku hiperalgeziju
Nociceptivni termički prg osjetljivosti mjeren kod štakora korištenjem Hargreavesove aparature. Određivanje bazne linije (BL) je provedeno na životinjama prije davanja 100 µl 2% karagena intraplantarnom injekcijom. Rezultati su prikazani kao srednja vrijednost (±SEM) od 8 životinja po skupini. Gabapentin (GP) ili CI-1009 je davan s.c. 2.5 sata nakon karagena *P<0.05 i **P<0.01 znatno se razlikuju za kontrolnu skupinu tretiranu vehikulima (Veh.) (ANOVA nakon čega slijedi Dunnetov t-test).
Slika 4. Učinak (a) morfina, (b) gabapentina i (c) (S)-(+)-3-izobutilgaba na termičku hiperalgeziju u modelu štakora s postoperativnom boli
Gabapentin ili (S)-(+)-3-izobutilgaba davani su 1 sat prije operacije. Morfin je davan 0.5 sati prije operacije. Termička latencija povlačenje šape (PWL, engl. paw withdrawal latencies) utvrđena je za ipsilateralne i kontalateralne šape korištenjem plantarnog testa na štakorima. Zbog jasnosti nisu dani podaci za kontalateralne šape lijekom tretiranih životinja. Određivanje bazne linije (BL) je provedeno na životinjama prije operacije i PWL je ponovo određen 2, 24, 48 i 72 sata poslije operacije. Rezultati su prikazani kao PWL srednja vrijednost od 8 do 10 životinja po skupini (vertikalne crte predstavljaju ±SEM). *P<0.05 i **P<0.01 znatno se razlikuju (ANOVA nakon čega slijedi Dunnetov t-test) kad se usporedbi skupina kod koje se u ipsilateralne šape tretiranje lijekom, sa skupinom kod koje su ipsilateralne šape tretirane vehikulom u svakoj vremenskoj točki. U slici -λ- je vehikulima tretirana kontalateralna, -O- je vehikulima tretirana ipsialateralna, -Δ- je tretman s 1 mg/kg morfina, -Y- je 3, a -◊- je s 6 mg/kg morfin u 4a. U 4b -Δ- je 3, -Y- je 10, a -◊- tretman od 30 mg/kg gabapentin. U 4c -Δ- je tretman s 3 mg/kg, -Y- je 10, a -◊- je s 30 mg/kg S-(+)-izobutilgaba.
Slika 5 Učinak (a) morfolina, (b) gabapentina i (c) (S)-(+)-3-izobutilgaba na taktilnu alodiniju u modelu štakora s postoperavnom boli
Gabapentin ili (S)-(+)-3-izobutilgaba davani su 1 sat prije operacije. Morfin je davan 05 sati prije operacije. Prag povlačenja šapa za von Freyeve niti filmenata je utvrđen za ipsilateralne i kontralateralne šape. Zbog jasnosti nisu dani podaci za kontralateralne šape lijekom tretiranih životinja. Određivanje bazne linije (BL) je provedeno na životinjama prije operacije i prag povlačenja šapa je određen 3, 25, 49 i 73 sata poslije operacije. Rezultati su prikazani kao medijalna sila (g) potrebna da izazove povlačenje šapa u skupini od 8 do 10 životinja. *P<0.05 i **P<0.01 znatno se razlikuju (Mann Whitney t-test) kad se usporedi skupina kod koje su ipsilateralne šape tretiranje lijekom, sa skupinom kod koje su ipsilateralne šape tretirane vehikulom i svakoj vremenskoj točki. U slici -λ- je vehikulima tretirana kontralateralna, -O- vehikulima tretirana ipsilateralna, -Δ- je 1 mg/kg morfina, -Y- je 3, a -◊- je 16. U 5b gabapentin i S-(+)-izobutilgaba, Δ- označuje tretaman s 3 mg/kg, -Y- je 10, a -◊- je 30.
Slika 6. Učinak S-(+)izobutilgaba na održavanje (a) termičke hiperalgezije i (b) taktilne alodinije u modelu štakora s postoperativnom boli
(S)-(+)-3-izobutilgaba ((S)-(+)-3-IBG dana je 1 sat nakon operacije. Morfin je davan 0,5 sati prije operacije. Termička latencija povlačenja šape plantarnim testom i prag povlačenja šapa s von Freywvim niti je određeni su u posebnoj skupini životinja za ipsilateralne i kontralateralne šape. Zbog jasnosti nisu dani podaci za kontralateralne šape lijekom tretiranih životinja. Određivanje bazne linije (BL) je provedeno na životinjama prije operacije i prag povlačenja je ponovno odrađen 6 sati poslije operacije. Za termičku hiperalgeziju rezultati su prikazani kao srednja vrijednost PWL od 6 životinja po skupini (vertikalne crte predstavljaju ±SEM), *P<0.05 i **P<0.01 znatno se razlikuju (nespareni t-test)) kad se usporedi skupina kod koje su ipsilateralne šape tretiranje vehikulom (veh. -O-) u svakoj vremenskoj točki. Za taktilnu alodiniju, rezultati su izraženi kao srednja sila (g) potrebno da izazove povlačenje šape 6 životinja po skupini. *P<0.05 i **P<0.01 se znatno razlikuju (Mann Whitney t-test) kad se usporedi skupina kod koje su ipsilateralne šape tretirane lijekom, sa skupinom kod koje su ipsilateralne šape tretirane vehikulom u svakoj vremenskoj točki. -λ- je S-(+)-IBG pri tretmanu od 30 mg/kg.
Detaljan opis
Ovaj izum prikazuje metodu korištenja spoja gornje formule I kao analgetika za tretman gore nabrojanih bolova. Posebice su obuhvaćeni: bol uzrokovana upalom, neuropatska bol, bol uzrokovana karcinomom, postoperativna bol i idiopatska bol, koja je bol nepoznatog porijekla, primjerice fantomska bol udova. Neuropatična bol uzrokovana je ozljedom ili infekcijom perifernih senzornih živaca. Također je uključena, ali bez ograničenja, živčana trauma, kausalgija, avulzija pleksusa, neurona, amputacija udova i vaskulitis. Neuropatska bol također može biti uzrokovana oštećenjem od kroničnog alkoholizma, virusne infekcije humane imunodeficijencije, hipotirodizma, uremije ili nedostatku vitamina. Neuropatična bol uključuje, ali bez ograničenja na to, ozljedu živca kao što je primjerice bol od koje pate dijabetičari.
Poznato je da su gore navedena stanja slabo tretirana od postojećih analgetika na tržištu, koji su primjerice narkotici ili nesteroidni antiuplani lijekovi (NSAAID), a zbog nedovoljne učinkovitosti i nuzefekta koji ograničavaju njihovu upotrebu.
Termini korišteni u formuli I su primjerice alkil, termin koji označava metil, etil, propil, izopropil, n-butil, izobutil, sec-butil, tert-butil, izopentil i neopentil, kao i one koji će biti očiti stručnjacima.
Primjeri za termin "cikloalkil" jesu ciklopropil, ciklobutil, ciklopentil i cikloheksil.
Spojevi iz predstavljenog izuma mogu tovriti farmaceutski prihvatljive soli s organskim i anorganskim kiselinama i bazama. Primjerice, soli nastale adicijom kiseline na bazične spojeve se pripravljaju otapanjem slobodne baze u vodenoj ili vodeno alkoholnoj otopini ili u drugim pogodnim otapalima koji sadrže pogodnu kiselinu, te izoliranjem soli uparavanjem otopine. Primjeri farmaceutski prihvatljivih soli su hidrokloridi, hidrobromidi, hidrosulfati itd., kao i natrijeve, kalijeve, magnezijeve itd. soli.
Spojevi iz ovog izuma mogu sadržavati nekoliko asimetričnih ugljikovih atoma. Izum uključuje pojedine diastreomere ili enetiomere, te njihovu smjesu. Pojedini dijasteromeri ili enatiomeri se mogu pripraviti ili izolirati već poznatim metodama.
Metode priprave 3-alkil-4-aminobutanske kiseline polazeći iz 2-alkenoil estera pripravljeno je iz komercijalno pristupačnih aldehida i monoetilmalonata Knoevenagelovom reakcijom (Kim C., Cocolase G. H., J. Med. Chem. 1965:8509), s iznimkom etil-4,4-dimetil-2-pentenoata. ovaj spoj je pripravljen iz 2,2-dimetilpropanola i etil-litioacetata, nakon čega slijedi dehidratacija β-hidroksiestera s fosforil-kloridom i piridinom. Michaelovom adicijom nitrometana na α,β-nezasićene spojeve održavane 1,1,3,3-trimetilgvanidinom ili 1,8-diazabiciklo [5.4.0]undeka-7-en(DBU) pri čemu nitroester nastaje u dobrom iskorištenju.
Mada su alifatski nitro spojevi obično reducirani katalitičkim hidriranjem pod visokim tlakom, metalom kataliziranim prijenosom vodika ili novim metodama s amonijevim formijatom ili natrijevim borhidridom i paladijem kao katalizatorom, aplikanti su našli da se 4-nitrokarboksilni esteri mogu reducirati gotovo kvantitativno u odgovarajuće 4-aminokarboksilne estere hidriranjem korištenjem 10% paladija na ugljenu kao katalizatora u octenoj kiselini pri sobnoj temperaturi i pri atmosferskom tlaku. Nastali aminoesteri su podvrgnuti hidrolizi pri čemu je dobiven spoj iz izuma u dobrom iskorištenju. Postupak omogućuje dobivanje različitih 3-alkil-4-aminobutanskih kiselina, koje su prikazane u Tablici 1 i 2 kao primjeri, te ih je stoga pogodno uspoređivati s prethodno korištenim metodama.
Kada polazni materijal nije komercijalno pristupačan, sintetska sekvencija je započela s odgovarajućim alkoholom koji je oksidiran u aldehid metodom po Corey et al., Tetrahedron Lett., 1975:2647-2650.
Spojevi pripravljeni sintetskim metodama mogu se koristiti kao farmaceutski pripravci u tretmanu boli, a kada se koristi učinkovita količina spoja formule I skupa s farmaceutski prihvatljivim nosačem. Lijek se može koristiti za metodu tretmana takvih poremećaja kod sisavaca uključujući ljude koji od toga pate, a davanjem sisavcima učinkovite količine gore opisanog spoja u jedinici doze.
Farmaceutski pripravak načinjen prema ovom izumu se može pripraviti i davati u raznim oblicima doza za oralni ili parenteralni način davanja. Primjerice, ovi farmaceutski pripravci se mogu se načiniti u inertnom farmaceutski prihvatljivom nosaču koji je čvrst ili tekuć. Čvrsti oblici pripravaka uključuju praške, tablete, dispegivne granule, kapsule, vrećice i supozitorije. Ostali čvrsti i tekući pripravci se mogu načiniti u skladu s poznatim metodama i davati oralno u odgovarajućoj formulaciji ili parenteralno kao što je intravenoznom, intramuskularnom ili subkutanom injekcijom tekućeg pripravka.
Količina aktivne tvari u jedinici doze se može mijenjati ili podesiti od 1 mg do oko 300 mg/kg po danu, a na osnovi prosječnog pacijenta od 70 kg. Dnevna doza je 1 kg do oko 50 mg/kg preferirana. Doza se međutim može mijenjati ovisno o zahtjevima pacijenta, ozbiljnosti tretiranog stanja i korištenog spoja. Određivanje odgovarajuće doze za određenu situaciju je u području struke.
Učinak gabapentina, CI-1008 i 3-aminometil-5-metil-heksanske kiseline formalinskom testu na šape štakora
Mužjaci Spargue-Dawley štakora (70-90 g) su ostavljeni da se naviknu na prostor za promatranje načinjen od pespeksa (24 cm x 24 cm x 24 cm) najmanje 15 minuta prije testiranja. Formalinom izazvano lizanje i grickanje zadnje šape započeto je nakon 50 µl subkutano injektirane 5% otopine formalina (5% formaldehid u izotoničnoj fiziološkoj otopini) u plantarnu površinu lijeve stražnje šape. Odmah nakon injekcije formalina promatrano je lizanje/grickanje šape u koju je dana injekcija u razmacima od 5 minuta tijekom 60 minuta. Rezultati su izraženi kao kombinirano vrijeme lizanja/grickanja u ranoj fazi (0-10 minuta i u kasnoj fazi) 10-45 minuta).
Gabapentin s.c. davan (10-300 mg/kg) ili CI-1008 (1-100 mg/kg) 1 sat prije doze formalina, a ovisno o dozi zaustavili su lizanje/grickanje tijekom kasne faze djelovanja formalina s minimalnom efektivnom dozom (MED) od 30, odnosno 10 mg/kg (Slika 1). Međutim, ni jedan od tih spojeva nije djelovao na ranu fazu pri bilo kojoj dozi. Slično, davanje 3-aminometil-5-metil-heksanske kiseline rezultiralo je samo laganim smanjivanjem lizanja/grickanja u kasnoj fazi pri dozi od 100 mg/kg.
Učinak gabapentina i CI-1008 na karagenom izazvanu mehaničku hiperalgeziju
Drugog i trećeg testiranog dana određivanje bazne linije je provedeno prije nego je štakorima (Spargue-Dawley, 70-90 g) dano u 100 µl karagena intraplantarnom injekcijom u desnu zadnju šapu. Životinjama je dana doza testiranog lijeka nakon razvitka signala hiperalgezije. Za studij mehaničke i termičke hiperalgezije korištene su posebne skupine životinja.
A. Mehanička hiperalgezija
Nociceptivni prag na pritisak je mjeren pritiskom na šapu štakora korištenjem analgezimetra (Ugo Basile). Najveća težina je bila 250 g, a da bi se spriječilo oštećenje šape. Intraplantarna injekcija karagena uzrokovala je smanjenje neciceptivnog praga na pritisak između 3 i 5 sati nakon davanja injekcije, pokazujući izazivanje hiperalgezije. Morfin (3 mg/kg) je uzrokovao potpunu blokadu hiperalgezije (Slika 2). Gabapentin (3-300 mg/kg s.c.) i CI-1008 (1-100 mg/kg s.c.) su, ovisno o dozi antagonizirali hiperalgeziju s odgovarajućim MED od 10 i 3 mg/kg (Slika 2).
B. Termička hiperalgezija
Bazna linija latencije povlačenja šape (PWL, engl. paw withdrawal latencies) je određena za svakog štakora korištenjem Hargreavesovog modela. Karagen je injektiran kao što je gore opisano. Životinje su zatim bile testirane na termičku hiperalgeziju 2 sata nakon davanja karagena. Gabapentin (10-100 mg/kg) ili CI-1008 (1-30 mg/kg) je dan s.c. 2.5 sata nakon karagenina, i PWL je ponovo procijenjen 3 i4 sata nakon davanja karagena. Karagen je izazvao značajno smanjivanje latencije povlačenje šape 2, 3 i 4 sata nakon injekcije, pokazujući indukciju termičke hiperalgezije (slika 3). Gabapentin i CI-1008 ovisno o dozi su antagonizirali hiperalgeziju s MED od 10 i 3 mg/kg (Slika 2).
Ovi podaci pokazuju da su gabapentini CI-1008 učinkoviti u tretmanu boli uzrokovane upalom.
Test Bennetta G.J. pokazuje model životinje s perifernom mononeuropatijom u štakora koji uzrokuje poremećaj s osjećajem boli kao onaj viđen kod čovjeka (Pain, 1988:33:87-107).
Test Kimm S. H et al. pokazuje jedan eksperimentalni model životinje s perifernom mononeuropatijom uzrokovane segmentnim povezivanjem spiralnog živca u štakora (Pain, 1990:50:355-363).
Model štakora za postoperativnu bol je opisan (Brennnen et al., 1996). On obuhvaća inciziju koću, fascije i mišića u plantarnom aspektu zadnje šape. Ovo vodi do indukcije reproducibilne mjerljive mehaničke hiperalgezije koja traje nekoliko dana. Ukazano je da taj model pokazuje neke sličnosti s humanim postoperativnim stanjem boli. U ovom istraživanju ispitivali smo i uspoređivali aktivnost gabapentina i (S)-3-izobutilgaba s morfolinom u ovom modelu postoperativne boli.
METODE
Mužjaci Spargue-Dawley štakora (250-300 g) dobiveni of Bantin and Kingmen (Hull, U. K.) su korišteni u svim eksperimentima. Prije operacije, skupine životinja se izložene 6 do 12 satnim periodima mraka i svjetla naizmjenično (svjetlo je paljeno u 7 sati 0 minuta) s hranom i vodom ab libitum. Postoperativno su životinje smještene u parovima na “Aqua-sorb” podlogu koja se sastoji od sloja celuloze (Beta Medical i Scientific, Sale, U. K.) pod istim uvjetima. Svi eksperimenti su izvedeni od promatrača koji nije znao koja životinja je bila tretirana.
Operacija
Životinje su anestezirane s 2% izofluoranom i 1.4 O2/NO2 smjesom koja je održavana tijekom operacije preko nosne šupljine. Plantarna površina desne zadnje šape je obrađena s 50% etanolom i 1 cm longitudinalna incizija je načinjena preko koće i fascije, počevši od 0.5 cm do ruba pete i produljeni prema prstima. Plantarni mišići su podignuti korištenjem forcepsa i incizirani su longitudinalno. Rana je zatvorena korištenjem dviju jednostavnih šavova od svilenog konca s FST-02 iglom. Mjesto rane je pokriveno Terramycin sprejem i Auromycin praškom. Niti jedna životinja nije postoperativno pokazivala znakove infekcije i rane su dobro zacjeljivale nakon 24 sata. Konac je uklonjen nakon 48 sati.
Procjena termičke hiperalgezije
Termička hiperalgezija je određena korištenjem plantarnog testa na štakore (Ugo Basile, Italy) nakon čega je slijedila modificirana metoda Hargreavesa et al. 1988. Štakori su ostavljeni da se naviknu na aparaturu koja se sastoji od tri pojedinačne kutije od perspeksa na podignutom staklenom stolu. Pokretni izvor topline je smješten pod stol i fokusiran je na zadnju šapu i latencija povlačenja šape (PWL) je bilježena. Automatsko prekidanje je bilo kod 22.5 sekundi da se spriječi oštećenje tkiva. PWL su određeni 2 do 3 puta za obje zadnje šape od životinje, čija srednja vrijednost predstavlja baznu liniju za desnu i lijevu šapu. Aparatura je kalibrirana da pokazuje PWL približno 10 sekundi. PWL je ponovno određen korištenjem istog gornjeg protokola 2, 24, 48 i 72 sata postoperativno.
Proocjena taktilne alodinije
Taktilna alodinija je mjerena korištenjem Semmes-Weinstein von Freyevih niti (Stoelting, Illinois, U.S.A.). Životinje su smještene u kaveze s dnom od mrežaste žice, što omogućuje pristup donjem dijelu šapa. Životinje su ostavljene da se priviknu na okolinu prije početka eksperimenta. Taktilna alodinija je testirana dodirivanjem plantarne površine zadnjih šapa životinja s von Freyevom niti primjenjujući rastuću silu (0.7, 1.2, 1.5, 2, 3.6, 5.5, 11.8, 15.1 i 29 g), a sve dok nije izazvano povlačenje šape. Svaka von Freyeva nit je primjenjena na šapu 6 sekundi, ili do poajve odgovara. Kad je povlačenje utvrđeno, šapa je ponovno testirana počevši od slijedeće manje von Freyene niti, sve dok je odgovor povlačenja izostao. Najjača sila od 29 g je podigla šapu i izazvala odgovor, pa je stoga predstavljala granicu pokusa. Svakoj životinji su testirane obje zadnje šape na isti način. Najmanja sila koja je potrebna za izazivanje odgovora je zabilježena kao prag povlačenja u gramima. Kada je spoj dan prije operacije, iste životinje su korištene za studije učinka lijeka na taktilnu alodiniju 1 sat nakon termičke hiperalgezije. Posebne skupine životinja su korištene za istraživanje taktilne alodinije i termalne hiperalgizije, a kada je nakon operacije dana (S)-(+)-izobutilgaba.
Statistika
Podaci dobiveni za termičku hiperalgeziju su podvrgnuti ANOVa testu jedne veličine (analiza varijanti), nakon čega je slijedio Dunnettov t-test. Rezultati taktilne alodinije dobiveni s von Freyevim nitima podvrgnuti su pojedinačnom Man Whitneyovom t-testu.
REZULTATI
Incizija plantaris mišića u štakora vodi izazivanju termičke hiperalgezije i taktilne alodinije. Oba nociceptivna odgovora su postigla najjači intenzitet 1 sat nakon operacije i održavani su 3 dana. Tijekom eksperimentalnog perioda životinje su ostale dobrog zdravlja.
Učinak gabapentina, (S)-(+)-3-izobutilgaba i morfina davanih prije operacije na termičku hipoeralgeziju
Jedna doza gabapentina dana je 1 sat prije operacije, a ovisno o dozi (3-30 mg/kg) zaustavila je razvitak termičke hiperalgezije s MED od 30 mg/kg (Slika 1b). Najviša doza od 30 mg/kg gabapentina spriječila je hiperalgestični odgovor za 24 sata (Slika 1b). Slično davanje S-(+)-izobutilgaba ovisno o dozi (3-30 mg/kg), s. c.) sprječava razvitak termičke hiperalgezije s MED od 3 mg/kg (slika 1c). Davanje morfina 0.5 sata prije operacije ovisno o dozi (1.6 mg/kg, s. c.) antagonizira razvijanje termičke hiperalgezije s MED od 1 mg/kg (Slika 1a). Taj učinak je održavan 24 sata (Slika 1a).
Učinak gabapentina, S-(+)-3-iozobutilgaba i morfina davanih prije operacije na taktilnu alodiniju
Učinak lijekova na razvitak taktilne alodinije je određen na istim životinjama koje su korištene za test na taktilnu alodiniju. Gabapentin je ovisno o dozi spriječio razvitak taktilne alodinije s MED od 10 mg/kg. Doze od 10 i 30 mg/kg gabapentina su učinkovite za 25 i 49 sati (Slika 2b). S-(+)-3-izobutilgaba također ovisno o dozi (3-30 mg/kg) zaustavlja razvitak odgovora na alodiniju s MED od 10 mg/kg (slika 2c). Ovo zaustavljanje nociceptivnog odgovora je održavano 3 dana s dozom S-(+)-3-izobutilgaba od 30 mg/kg (Slika 2c). Nasuprot tome, morfin (1-6 mg/kg) samo sprječava razvitak taktilne alodinije za 3 sata poslije operacije, a pri najvišoj dozi od 6 mg/kg (Slika 2a).
Učinak S-(+)-3-izobutilgaba danog 1 sat nakon operacije na taktilnu alodiniju i termalnu hiperalgeziju
Alodinija i hiperalgezija su dostigle najjači intenzitet unutar 1 sata u svim životinjama i održavana je slijedećih 5 do 6 sati. Davanje s. c. od 30 mg/kg S-(+)-3-izobutilgaba 1 sat nakon operacije zaustavilo je održavanje taktilne alodinije i termičke hiperalgezije za 3 do 4 sata. Nakon tog vremena, oba nociceptivna odgovora vratila su se na razinu kontrole pokazujući nestajanje antihiperalergičnog i antilodiničkog djelovanja (Slika 3).
Gabapentin i S-(+)-izobutilgaba nisu utjecali na PWL niti u najvišim dozama tijekom testa na termičku hiperalgeziju ili taktilnu alodiniju u kontralateralnoj šapi niti u jednom eksperimentu. Nasuprot tome, morfin (6 mg s. c.) povećao je PWL kontralateralne šape pri termičkoj hiperalgeziji (podaci nisu pokazani).
Ovdje prikazani rezultati pokazuju da incizija planratis mišića štakora izaziva termičku hiperalgeziju i taktilnu aliodiniju koja traje najmanje 3 dana. Glavno otkriće predstavljenog izuma je da su gabapentin i S-(+)-izobutilgaba jednako učinkoviti u zaustavljanju nociceptivnih odgovora. Nasuprot tomu, našao je da je morfin učinkovitiji u tretmanu termičke hiperalgezije nego taktilne alodinije. Nadalje, S-(+)-izobutilgaba potpuno zaustavlja indukciju i održavanje alodinije i hiperalgezije.
Claims (15)
1. Metoda tretmana boli, naznačeno time, da sadrži davanje terapijski učinkovite količine spoja formule I
[image]
ili je odgovarajuće farmaceutski prihvatljive soli, pri čemu
R1 jeste ravni ili razgranati alkil od 1 do 6 atoma ugljika, fenil ili cikloalkil od 3 do 6 atoma ugljika,
R2 je vodik ili metil, te
R3 je vodik, metil ili karboksil.
2. Metoda prema patentnom zahtjevu 1, naznačeno time, da je spoj koji se daje formule I u kojoj R2 i R3 jesu vodici, a R1 je -(CH2)0-2- i C4H9 u obliku (R), (S) ili (R,S) izomera.
3. Metoda prema patentnom zahtjevu 1, naznačeno time, da se spoj koji se daje naziva (S)-3-(aminometil)-5-metilheksanska kiselina i 3-aminometil-5-metil-heksanska kiselina.
4. Metoda prema patentnom zahtjevu 1, naznačeno time, da se tretira bol uzrokovana upalom.
5. Metoda prema patentnom zahtjevu 1, naznačeno time, da se tretira neuropatična bol.
6. Metoda prema patentnom zahtjevu 1, naznačeno time, da se tretira bol uzrokovana karcinomom.
7. Metoda prema patentnom zahtjevu 1, naznačeno time, da se tretira postoperativna bol.
8. Metoda prema patentnom zahtjevu 1, naznačeno time, da se tretira fantomska bol udova.
9. Metoda prema patentnom zahtjevu 1, naznačeno time, da se tretira bol uzrokovana opeklinom.
10. Metoda prema patentnom zahtjevu 1, naznačeno time, da se tretira bol uzrokovana gihtom.
11. Metoda prema patentnom zahtjevu 1, naznačeno time, da se tretira osteoatritična bol.
12. Metoda prema patentnom zahtjevu 1, naznačeno time, da se tretira bol uzrokovana neuralgijom trigeminusa.
13. Metoda prema patentnom zahtjevu 1, naznačeno time, da se tretira herpetična i postherpetična i postherpetična bol.
14. Metoda prema patentnom zahtjevu 1, naznačeno time, da se tretira bol uzrokovana kauzalgijom.
15. Metoda prema patentnom zahtjevu 1, naznačeno time, da se tretira idiopatska bol.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2233796P | 1996-07-24 | 1996-07-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP970387A2 true HRP970387A2 (en) | 1998-10-31 |
Family
ID=21809080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR60/022,337A HRP970387A2 (en) | 1996-07-24 | 1997-07-17 | Isobutylgaba and its derivatives for the treatment of pain |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US6001876A (hr) |
| EP (1) | EP0934061B3 (hr) |
| JP (1) | JP3693258B2 (hr) |
| KR (1) | KR100491282B1 (hr) |
| CN (1) | CN1094757C (hr) |
| AT (1) | ATE241351T1 (hr) |
| AU (1) | AU714980B2 (hr) |
| BR (1) | BR9710536A (hr) |
| CA (1) | CA2255652C (hr) |
| CU (1) | CU22850A3 (hr) |
| DE (1) | DE69722426T3 (hr) |
| DK (1) | DK0934061T6 (hr) |
| ES (1) | ES2200184T7 (hr) |
| HK (1) | HK1021134A1 (hr) |
| HR (1) | HRP970387A2 (hr) |
| HU (2) | HU228426B1 (hr) |
| IL (1) | IL126999A (hr) |
| NO (2) | NO325822B1 (hr) |
| NZ (1) | NZ332762A (hr) |
| PL (1) | PL189872B1 (hr) |
| PT (1) | PT934061E (hr) |
| SI (1) | SI0934061T1 (hr) |
| WO (1) | WO1998003167A1 (hr) |
| ZA (1) | ZA976562B (hr) |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6329429B1 (en) | 1997-06-25 | 2001-12-11 | Warner-Lambert Company | Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases |
| HRP980342A2 (en) * | 1997-06-25 | 1999-02-28 | Warner Lambert Co | Anti-inflammatory method |
| ATE311867T1 (de) * | 1997-09-08 | 2005-12-15 | Warner Lambert Co | Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen |
| EP0974351A3 (en) * | 1998-04-24 | 2000-12-13 | Jouveinal | Medicament for preventing and treating gastrointestinal damage |
| HU228771B1 (en) * | 1998-05-15 | 2013-05-28 | Warner Lambert Co | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same |
| NZ509230A (en) * | 1998-07-09 | 2003-08-29 | Warner Lambert Co | Use of GABA analogs to treat renal colic |
| ID27395A (id) * | 1998-07-09 | 2001-04-05 | Warner Lambert Co | Komposisi obat-obatan yang mengandung analog-analog gaba dan suatu bahan anti virus untuk mengobati penyakit ruam syaraf |
| US6680343B1 (en) | 1998-07-09 | 2004-01-20 | Warner-Lambert Comapny | Treatment of renal colic with GABA analogs |
| US20030045500A1 (en) * | 1998-07-09 | 2003-03-06 | Leslie Magnus | Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles |
| PL345703A1 (en) * | 1998-07-09 | 2002-01-02 | Warner Lambert Co | Compositions comprising gaba analogs and a decongestant to relieve sinus headache pain |
| US6992109B1 (en) * | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| AU3735000A (en) * | 1999-05-05 | 2000-11-21 | Warner-Lambert Company | Modulation of substance p by gaba analogs and methods relating thereto |
| US7164034B2 (en) * | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
| ES2317839T3 (es) * | 1999-06-10 | 2009-05-01 | Warner-Lambert Company Llc | Acidos 3-propil gamma-aminobutiricos monosustituidos. |
| US20080207755A1 (en) * | 2000-05-31 | 2008-08-28 | Pfizer Inc | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders |
| EP1840117A1 (en) * | 1999-06-10 | 2007-10-03 | Warner-Lambert Company LLC | Mono- and disubstituted 3-propyl gamma-aminobutyric acids |
| IL152925A (en) * | 1999-10-21 | 2010-04-15 | Pfizer | Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin |
| EA004934B1 (ru) * | 2000-01-27 | 2004-10-28 | Уорнер-Ламберт Компани | Асимметрический синтез прегабалина |
| US6687187B2 (en) * | 2000-08-11 | 2004-02-03 | Phonak Ag | Method for directional location and locating system |
| CA2356829A1 (en) * | 2000-09-22 | 2002-03-22 | Warner-Lambert Company | Method for treating asthma using pregabalin |
| US6620829B2 (en) * | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
| GB2368579A (en) * | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
| ES2262567T3 (es) * | 2001-03-20 | 2006-12-01 | Schwarz Pharma Ag | Nuevo uso de una clase peptidica de compuesto para tratamiento del dolor inflamatorio no neuropatico. |
| PT1243263E (pt) * | 2001-03-21 | 2003-03-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| AU2002345638A1 (en) * | 2001-06-11 | 2002-12-23 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| NZ567711A (en) | 2001-06-11 | 2009-10-30 | Xenoport Inc | Orally administered dosage forms of GABA analog prodrugs having reduced toxicity |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7232924B2 (en) * | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| PT1423168E (pt) | 2001-09-03 | 2006-05-31 | Newron Pharm Spa | Composicao farmaceutica que compreende gabapentina ou um seu analogo e uma x-aminoamida e a sua utilizacao como analgesico |
| EP1485082A4 (en) | 2002-02-19 | 2009-12-30 | Xenoport Inc | PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS |
| WO2003099338A2 (en) * | 2002-05-17 | 2003-12-04 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| GB0219024D0 (en) * | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
| US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| US7060727B2 (en) * | 2002-12-11 | 2006-06-13 | Xenoport, Inc. | Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof |
| WO2004053192A1 (en) * | 2002-12-11 | 2004-06-24 | Xenoport, Inc. | Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| NZ540336A (en) * | 2002-12-13 | 2008-03-28 | Warner Lambert Co | Gabapentin analogues for fibromyalgia and other related disorders |
| JP2006513257A (ja) * | 2002-12-13 | 2006-04-20 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 線維筋痛症および他の障害を処置するためのプレガバリン誘導体 |
| CA2508297A1 (en) * | 2002-12-13 | 2004-07-01 | Warner-Lambert Company Llc | Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders |
| KR20050085563A (ko) | 2002-12-13 | 2005-08-29 | 워너-램버트 캄파니 엘엘씨 | 하부요로증상을 치료하기 위한 알파-2-델타 리간드 |
| US20080318908A1 (en) * | 2002-12-17 | 2008-12-25 | Trustees Of Tufts College | Use of gaba and gabab agonists |
| BRPI0414343A (pt) * | 2003-09-12 | 2006-11-07 | Pfizer | combinações que compreendem ligantes de alfa-2-delta e inibidores da reabsorção de serotonina/noradrenalina |
| EP1677812A4 (en) * | 2003-09-17 | 2010-03-24 | Xenoport Inc | TREATMENT OR PREVENTION OF NON-REST LEG SYNDROME USING GABA ANALOGUE-BASED PRODRUGS |
| MXPA06004088A (es) | 2003-10-14 | 2006-06-27 | Xenoport Inc | Forma cristalina de un analogo del acido gamma-aminobutirico. |
| NZ546576A (en) * | 2003-12-02 | 2009-05-31 | Sanol Arznei Schwarz Gmbh | Use of peptide compounds for treating central neuropathic pain |
| DK1727620T3 (da) * | 2004-03-12 | 2007-12-03 | Warner Lambert Co | C1 symmetriske biphosphinlegander og deres anvendelse i asymmetrisk syntese af pregabilin |
| US20100256179A1 (en) * | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
| US20070042969A1 (en) * | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
| CA2561755A1 (en) * | 2004-04-01 | 2005-10-13 | Warner-Lambert Company Llc | Preparation of p-chirogenic phospholanes and their use in asymmetric synthesis |
| KR20070007931A (ko) | 2004-04-16 | 2007-01-16 | 쉬바르츠파르마에이지 | 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도 |
| EP1604655A1 (en) * | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| EA015418B1 (ru) * | 2004-06-21 | 2011-08-30 | УОРНЕР-ЛАМБЕРТ КОМПАНИ ЭлЭлСи | Получение прегабалина и родственных соединений |
| JP2008510758A (ja) * | 2004-08-27 | 2008-04-10 | シュヴァルツ・ファーマ・アーゲー | 骨肉腫の痛み、化学療法誘発性及びヌクレオシド誘発性の痛みを治療するためのペプチド化合物の新規使用 |
| KR101228399B1 (ko) * | 2004-11-04 | 2013-01-31 | 제노포트 인코포레이티드 | 가바펜틴 프로드러그 서방성 경구 투여 형태 |
| ATE523484T1 (de) * | 2005-05-10 | 2011-09-15 | Teva Pharma | Optische lösung a us 3-carbamoylmethyl-5-methyl- hexansäure |
| EP1879851B1 (en) * | 2005-05-10 | 2010-11-03 | Teva Pharmaceutical Industries Ltd | Method for the preparation of pregabalin and salts thereof |
| US20080293698A1 (en) * | 2005-05-16 | 2008-11-27 | Joseph Johnson | Methods and Compositions for Treating Arg |
| EP1940380A2 (en) * | 2005-05-20 | 2008-07-09 | Pfizer Limited | Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-2 delta-ligands |
| EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| ES2398579T3 (es) * | 2005-09-19 | 2013-03-20 | Teva Pharmaceutical Industries Ltd | Una síntesis asimétrica de ácido (S)-(+)-3-(aminometil)-5-metilhexanoico |
| EP2019817A2 (en) * | 2006-05-24 | 2009-02-04 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of r-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof |
| MX2008016000A (es) | 2006-06-15 | 2009-03-05 | Sanol Arznei Schwarz Gmbh | Composicion farmaceutica con efecto anticonvulsivante sinergistico. |
| US8097754B2 (en) * | 2007-03-22 | 2012-01-17 | Teva Pharmaceutical Industries Ltd. | Synthesis of (S)-(+)-3-(aminomethyl)-5-methyl hexanoic acid |
| WO2009046309A2 (en) * | 2007-10-03 | 2009-04-09 | Teva Pharmaceutical Industries Ltd. | Pregabalin -4-eliminate, pregabalin 5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof |
| KR20100107500A (ko) * | 2008-06-23 | 2010-10-05 | 테바 파마슈티컬 인더스트리즈 리미티드 | (ｓ) 또는 (ｒ)-이소-부틸-글루타릭 에스테르의 입체선택적 효소 합성방법 |
| WO2010070593A2 (en) | 2008-12-19 | 2010-06-24 | Pfizer Ireland Pharmaceuticals | Malonate esters |
| EP2400989B1 (en) | 2009-02-24 | 2016-08-10 | Nektar Therapeutics | Gabapentin-peg conjugates |
| EP2429991B1 (en) * | 2009-05-15 | 2014-09-10 | Redx Pharma Limited | Redox drug derivatives |
| WO2010150221A1 (en) | 2009-06-25 | 2010-12-29 | Wockhardt Research Centre | Taste masked pharmaceutical compositions of pregabalin |
| US20110130454A1 (en) * | 2009-11-24 | 2011-06-02 | Xenoport, Inc. | Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
| US20110124705A1 (en) * | 2009-11-24 | 2011-05-26 | Xenoport, Inc. | Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
| WO2011071995A2 (en) | 2009-12-08 | 2011-06-16 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
| HU230031B1 (hu) | 2010-03-01 | 2015-05-28 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény |
| WO2011141923A2 (en) | 2010-05-14 | 2011-11-17 | Lupin Limited | Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin |
| WO2011151708A1 (en) | 2010-06-01 | 2011-12-08 | Rubicon Research Private Limited | Gastroretentive dosage forms of gaba analogs |
| WO2012025861A1 (en) | 2010-08-23 | 2012-03-01 | Pfizer Manufacturing Ireland | Process for the preparation of ( s ) - 3 - cyano - 5 - methylhexanoic acid derivatives adn of pregabalin |
| US8466297B2 (en) | 2010-11-01 | 2013-06-18 | Milan Soukup | Manufacturing process for (S)-Pregabalin |
| WO2012059797A1 (en) | 2010-11-04 | 2012-05-10 | Lupin Limited | Process for synthesis of (s) - pregabalin |
| AU2013213769A1 (en) | 2012-01-30 | 2014-08-21 | Sun Pharmaceutical Industries Limited | Gastroretentive tablets |
| AU2013213859A1 (en) | 2012-01-30 | 2014-08-21 | Sun Pharmaceutical Industries Limited | Pregabalin GR tablets |
| CN102966602B (zh) * | 2012-12-14 | 2015-08-05 | 江苏海鸥冷却塔股份有限公司 | 一种冷却塔节能导流风筒 |
| EP2946777B1 (en) | 2013-01-18 | 2023-10-04 | Kemphys Ltd. | Medicine for treatment of neuropathic disease |
| DK2978748T3 (en) | 2013-03-27 | 2017-07-24 | Pfizer Ireland Pharmaceuticals | Process and intermediates for the preparation of pregabalin |
| WO2016187718A1 (en) | 2015-05-26 | 2016-12-01 | Isa Odidi | Controlled extended release pregabalin |
| GB201617380D0 (en) | 2016-10-13 | 2016-11-30 | St George's Hospital Medical School | Treatment for Osteoarthritis |
| KR102039345B1 (ko) | 2017-02-01 | 2019-11-01 | 지엘팜텍주식회사 | 프레가발린 함유 고팽윤성 서방성 삼중정제 |
| KR102039344B1 (ko) | 2017-02-01 | 2019-11-01 | 지엘팜텍주식회사 | 프레가발린 함유 경구용 서방성 삼중정제 |
| GB201703123D0 (en) | 2017-02-27 | 2017-04-12 | St George's Hospital Medical School | Biomarkers |
| BR112020022885A2 (pt) | 2018-05-14 | 2021-03-23 | Xgene Pharmaceutical Inc. | formas cristalinas de conjugados de fármacos de carbamato de 1-(aciloxi)-alquila de naproxeno e pregabalina |
| CN108926573A (zh) * | 2018-07-03 | 2018-12-04 | 泓博元生命科技（深圳）有限公司 | 一种可降低尿酸指数的nadh组合物及其制备方法及应用 |
| KR20200056719A (ko) | 2018-11-15 | 2020-05-25 | 단국대학교 천안캠퍼스 산학협력단 | 가바펜티노이드를 포함하는, 척수손상 개체의 신경재생 또는 신경회복을 위한 조성물 |
| WO2021191108A1 (en) | 2020-03-23 | 2021-09-30 | Plus Vitech, S.L. | Treatment or prevention of acute organ damage induced by viral infection with a nk1 inhibitor and/or a gabapentinoid |
| WO2022038131A1 (en) | 2020-08-19 | 2022-02-24 | Plus Vitech, S.L. | Method for the prediction of progression or prognosis of the response of a subject suffering from acute organ damage |
| WO2022234110A1 (en) | 2021-05-07 | 2022-11-10 | Plus Vitech, S.L. | Gamma-aminobutyric acid derivatives for use in cancer therapy |
| WO2022243430A1 (en) | 2021-05-20 | 2022-11-24 | Plus Vitech, S.L. | Treatment of acne |
| WO2022253748A1 (en) | 2021-06-03 | 2022-12-08 | Plus Vitech, S.L. | Combinations for the treatment of hpv |
Family Cites Families (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH449645A (de) | 1963-07-09 | 1968-01-15 | Ciba Geigy | Verfahren zur Herstellung neuer Aminosäuren |
| JPS4940460Y2 (hr) | 1971-05-19 | 1974-11-06 | ||
| DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| US4123438A (en) | 1975-03-05 | 1978-10-31 | Stamicarbon, B.V. | Process for preparing 2-pyrrolidones |
| NZ194348A (en) | 1979-07-26 | 1982-09-14 | Merrell Toraude & Co | Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions |
| US4322440A (en) | 1980-06-25 | 1982-03-30 | New York University | Anticonvulsive compositions and method of treating convulsive disorders |
| US4513135A (en) | 1982-03-05 | 1985-04-23 | Eli Lilly And Company | Diaryl-pyrazine derivatives affecting GABA binding |
| DK373383A (da) | 1982-08-20 | 1984-02-21 | Midit | Fremgangsmaade til fremstilling af omega-aminosyrederivater |
| US4479005A (en) | 1982-12-16 | 1984-10-23 | The Dow Chemical Company | Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids |
| DE133795T1 (de) | 1983-08-01 | 1985-09-12 | The Mclean Hospital Corp., Belmont, Mass. | Gaba-ester und gaba-analoge ester. |
| US5051448A (en) | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
| GB8425872D0 (en) | 1984-10-12 | 1984-11-21 | Ciba Geigy Ag | Chemical compounds |
| NO166131C (no) | 1985-06-20 | 1991-06-05 | Daiichi Seiyaku Co | Analogifremgangsmaate for fremstilling av s(-)-pyridobenzoksazinforbindelser. |
| US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| JP2535001B2 (ja) | 1987-01-13 | 1996-09-18 | ダイセル化学工業株式会社 | Ｎ−アルキル化アミノ酸エステルの製法 |
| JPH07116064B2 (ja) | 1987-07-21 | 1995-12-13 | 三菱化学株式会社 | 分離剤 |
| US4908210A (en) | 1988-10-28 | 1990-03-13 | Eastman Kodak Company | Lactylic salt tablet formulations and tablets |
| GB8911017D0 (en) | 1989-05-13 | 1989-06-28 | Ciba Geigy Ag | Substituted aminoalkylphosphinic acids |
| DE3928183A1 (de) | 1989-08-25 | 1991-02-28 | Goedecke Ag | Lactamfreie cyclische aminosaeuren |
| GB8921304D0 (en) | 1989-09-20 | 1989-11-08 | Wyeth John & Brother Ltd | New method of treatment and heterocyclic compounds used therein |
| US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
| US5084479A (en) | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
| US5025035A (en) | 1990-10-12 | 1991-06-18 | Warner-Lambert Company | Method of treating depression |
| US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| WO1992009560A1 (en) | 1990-11-27 | 1992-06-11 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
| WO1992014443A1 (en) | 1991-02-20 | 1992-09-03 | Warner-Lambert Company | Microsphere-in-oil emulsion |
| DK204791D0 (da) | 1991-12-20 | 1991-12-20 | Novo Nordisk As | Hidtil ukendt farmaceutisk praeparat |
| DK0641330T3 (da) | 1992-05-20 | 2001-12-03 | Univ Northwestern | Gaba- og L-glutaminsyreanaloger til antikrampeanfaldsbehandling |
| GB9308430D0 (en) | 1993-04-23 | 1993-06-09 | Glaxo Group Ltd | Medicaments |
| US5492927A (en) | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
| US5652216A (en) | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
| US5792796A (en) | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
| PL187064B1 (pl) | 1994-07-27 | 2004-05-31 | Warner Lambert Co | Zastosowania gabapentyny do leczenia i/lub zapobiegania stanom lękowym |
| GB9420784D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Group Ltd | Medicaments |
| US5767117A (en) | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
| JP3925662B2 (ja) | 1995-01-12 | 2007-06-06 | グラクソ，グループ，リミテッド | タキキニンアンタゴニスト活性を有するピペリジン誘導体 |
| ZA961591B (en) | 1995-02-28 | 1996-08-28 | Lundbeck & Co As H | 4-aminotetrahydrobenzisoxazole or -isothiazole compounds |
| US5510381A (en) | 1995-05-15 | 1996-04-23 | Warner-Lambert Company | Method of treatment of mania and bipolar disorder |
| US5616793A (en) | 1995-06-02 | 1997-04-01 | Warner-Lambert Company | Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid |
| US5637767A (en) | 1995-06-07 | 1997-06-10 | Warner-Lambert Company | Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid |
| ES2176668T3 (es) | 1996-02-07 | 2002-12-01 | Warner Lambert Co | Aminoacidos ciclicos novedosos como agentes farmaceuticos. |
| KR100512506B1 (ko) | 1996-03-14 | 2005-12-21 | 워너-램버트 캄파니 엘엘씨 | 제약제제로서신규한치환시클릭아미노산 |
| CZ287598A3 (cs) | 1996-03-14 | 1999-02-17 | Warner-Lambert Company | Přemostěné cyklické aminokyseliny |
| US20020077461A1 (en) | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| US6372792B1 (en) | 1996-04-26 | 2002-04-16 | Guy Chouinard | Method for treating anxiety, anxiety disorders and insomnia |
| JP2000514047A (ja) | 1996-06-26 | 2000-10-24 | ワーナー―ランバート・コンパニー | 催吐の処置用医薬の製造のためのタキキニンアンタゴニストの使用 |
| SE9603408D0 (sv) | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| US6329429B1 (en) | 1997-06-25 | 2001-12-11 | Warner-Lambert Company | Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases |
| HRP980342A2 (en) | 1997-06-25 | 1999-02-28 | Warner Lambert Co | Anti-inflammatory method |
| AU9019198A (en) | 1997-08-19 | 1999-03-08 | Warner-Lambert Company | Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants |
| AU8668598A (en) | 1997-08-20 | 1999-03-08 | University Of Oklahoma, The | Gaba analogs to prevent and treat gastrointestinal damage |
| US6127418A (en) | 1997-08-20 | 2000-10-03 | Warner-Lambert Company | GABA analogs to prevent and treat gastrointestinal damage |
| ATE311867T1 (de) | 1997-09-08 | 2005-12-15 | Warner Lambert Co | Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen |
| KR20010033154A (ko) | 1997-12-16 | 2001-04-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 제약물로서의 신규한 아민 |
| HU228771B1 (en) | 1998-05-15 | 2013-05-28 | Warner Lambert Co | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same |
| BR9910494B1 (pt) | 1998-05-15 | 2011-11-01 | composições sólidas contendo derivados de ácido gama-aminobutìrico e processo para o seu preparo. | |
| WO2000002546A2 (en) | 1998-07-09 | 2000-01-20 | Warner-Lambert Company | Use of caba-analogues for treating insomnia |
| US6680343B1 (en) | 1998-07-09 | 2004-01-20 | Warner-Lambert Comapny | Treatment of renal colic with GABA analogs |
| JP2002520286A (ja) | 1998-07-09 | 2002-07-09 | ワーナー−ランバート・カンパニー | Ｇａｂａ類縁体及びカフェインを含んでなる組成物 |
| US20030045500A1 (en) | 1998-07-09 | 2003-03-06 | Leslie Magnus | Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles |
| EP1121114B1 (en) | 1998-10-16 | 2007-01-10 | Warner-Lambert Company Llc | Use of gaba analogs for the manufacture of a medicament for the treatment of mania and bipolar disorders |
| EP1161263A1 (en) | 1999-03-10 | 2001-12-12 | Warner-Lambert Company Llc | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| US6992109B1 (en) | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| JP2002541224A (ja) | 1999-04-09 | 2002-12-03 | ワーナー−ランバート・カンパニー | うつ病の治療のためのｇａｂａ類縁体と三環系化合物の組合わせ |
| BR0011236A (pt) | 1999-06-02 | 2002-03-05 | Warner Lambert Co | Amino heterociclos úteis como agentes farmacêuticos |
| US6642398B2 (en) | 1999-06-10 | 2003-11-04 | Warner-Lambert Company | Mono-and disubstituted 3-propyl gamma-aminobutyric acids |
| US7164034B2 (en) | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
| MXPA02000170A (es) | 1999-07-02 | 2002-07-02 | Warner Lambert Co | Una combinacion sinergica: gabapentin y pregablin. |
| US7030119B1 (en) | 1999-07-16 | 2006-04-18 | Warner-Lambert Company | Method for treating chronic pain using MEK inhibitors |
| BR0014090A (pt) | 1999-09-16 | 2002-05-21 | Warner Lambert Co | Método para rastreamento de ligandos de ligação à subunidade alfa2delta-1 |
| AP2002002501A0 (en) | 1999-10-07 | 2002-06-30 | Warner Lambert Co | Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog. |
| EA004934B1 (ru) | 2000-01-27 | 2004-10-28 | Уорнер-Ламберт Компани | Асимметрический синтез прегабалина |
| US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| AU2001259627A1 (en) | 2000-05-16 | 2001-11-26 | Warner Lambert Company | Cell line for the expression of an alpha2delta2 calcium channel subunit |
| GB2365425A (en) | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
| CA2356829A1 (en) | 2000-09-22 | 2002-03-22 | Warner-Lambert Company | Method for treating asthma using pregabalin |
| US6620829B2 (en) | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
| PT1337271E (pt) | 2000-11-30 | 2005-01-31 | Pfizer Prod Inc | Combinacao de agonistas de gaba e inibidores de sorbitol desidrogenase |
| BR0115776A (pt) | 2000-11-30 | 2004-01-13 | Pfizer Prod Inc | Combinações de agonistas de gaba e inibidores da aldose redutase |
| MXPA03004168A (es) | 2000-12-13 | 2004-12-02 | Warner Lambert Co | Sintesis de ligandos bisfosfolanos p-quirales y de sus complejos con metales de transicion para uso como catalizadores de hidrogenacion asimetrica. |
| US20040002543A1 (en) | 2001-02-16 | 2004-01-01 | Leslie Magnus | Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain |
| ES2240657T3 (es) | 2001-02-28 | 2005-10-16 | Pfizer Products Inc. | Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa. |
| MXPA02001147A (es) | 2001-03-19 | 2004-04-21 | Warner Lambert Co | Sintesis de ligandos bisfosina no-c2-simetricos como catalizadores para la hidrogenacion asimetrica. |
| US7022678B2 (en) | 2001-03-30 | 2006-04-04 | Warner-Lambert Company | Pregabalin lactose conjugates |
| DE60202452C5 (de) | 2001-03-30 | 2006-11-23 | Pfizer Products Inc., Groton | Pyridazinonaldose reductase inhibitoren |
| EP1247809A3 (en) | 2001-03-30 | 2003-12-17 | Pfizer Products Inc. | Triazine compounds useful as sorbitol dehydrogenase inhibitors |
| KR100618743B1 (ko) | 2001-04-19 | 2006-08-31 | 워너-램버트 캄파니 엘엘씨 | 융합된 비사이클릭 또는 트리사이클릭 아미노산 |
| ES2265040T3 (es) | 2001-05-25 | 2007-02-01 | Warner-Lambert Company Llc | Composicion farmaceutica liquida. |
| US20030045449A1 (en) | 2001-08-15 | 2003-03-06 | Pfizer, Inc. | Pharmaceutical combinations for the treatment of neurodegenerative diseases |
| DE10203122A1 (de) | 2002-01-25 | 2003-07-31 | Gruenenthal Gmbh | Verfahren zur Herstellung von substituierten Acrylsäureestern bzw. deren Einsatz zur Herstellung von substituierten gamma-Aminosäuren |
| EP1469841A1 (en) | 2002-01-31 | 2004-10-27 | Warner-Lambert Company | Alpha 2 delta ligands to treat tinnitus |
| US6855724B2 (en) | 2002-04-08 | 2005-02-15 | Agouron Pharmaceuticals, Inc. | Tropane derivatives useful in therapy |
| US6713490B2 (en) | 2002-04-26 | 2004-03-30 | Pfizer, Inc. | 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists |
| US20030225149A1 (en) | 2002-04-30 | 2003-12-04 | Blazecka Peter G. | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids |
| MXPA04012922A (es) | 2002-06-27 | 2005-03-31 | Warner Lambert Co | Procedimiento para tratar el trastorno de hiperactividad con deficit de atencion. |
| WO2004005229A1 (en) | 2002-07-08 | 2004-01-15 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
| US7053122B2 (en) | 2002-08-09 | 2006-05-30 | Pfizer Inc | Therapeutic use of aryl amino acid derivatives |
| US20040092522A1 (en) | 2002-08-15 | 2004-05-13 | Field Mark John | Synergistic combinations |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| US7071339B2 (en) | 2002-08-29 | 2006-07-04 | Warner Lambert Company Llc | Process for preparing functionalized γ-butyrolactones from mucohalic acid |
| US7659305B2 (en) | 2002-10-31 | 2010-02-09 | Pfizer Inc. | Therapeutic proline derivatives |
| WO2004052373A1 (en) | 2002-12-06 | 2004-06-24 | Warner-Lambert Company Llc | Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k |
| CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| CA2508297A1 (en) | 2002-12-13 | 2004-07-01 | Warner-Lambert Company Llc | Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders |
| US7572910B2 (en) | 2003-02-20 | 2009-08-11 | Pfizer, Inc. | Pyridazinone aldose reductase inhibitors |
| RU2005135454A (ru) | 2003-05-16 | 2006-06-27 | Пфайзер Продактс Инк. (Us) | Терапевтические комбинации атипичных нейролептиков с модуляторами гамк и/или противосудорожными препаратами |
| EP1644360A1 (en) | 2003-06-05 | 2006-04-12 | Warner-Lambert Company LLC | 3-substituted indoles and derivatives thereof as therapeutic agents |
| EP1680125A1 (en) | 2003-07-02 | 2006-07-19 | Warner-Lambert Company LLC | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
| BRPI0414105B8 (pt) | 2003-09-03 | 2021-05-25 | Askat Inc | compostos de benzimidazolona com atividade agonista do receptor 5-ht4 |
| BRPI0414343A (pt) | 2003-09-12 | 2006-11-07 | Pfizer | combinações que compreendem ligantes de alfa-2-delta e inibidores da reabsorção de serotonina/noradrenalina |
| WO2005025563A1 (en) | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders |
| GB0322140D0 (en) | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| JP2007506729A (ja) | 2003-09-25 | 2007-03-22 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | α２δタンパク質に親和性を有するアミノ酸のプロドラッグ |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| EP1543831A1 (en) | 2003-12-18 | 2005-06-22 | Pfizer GmbH Arzneimittelwerk Gödecke | Pregabalin composition |
| WO2005082372A1 (en) | 2004-01-29 | 2005-09-09 | Pfizer Products Inc. | COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS |
| GB0405200D0 (en) | 2004-03-08 | 2004-04-21 | Pfizer Ltd | Combinations comprising alpha-2-delta ligands |
| DK1727620T3 (da) | 2004-03-12 | 2007-12-03 | Warner Lambert Co | C1 symmetriske biphosphinlegander og deres anvendelse i asymmetrisk syntese af pregabilin |
| CA2563164A1 (en) | 2004-03-29 | 2005-10-06 | Pfizer Inc. | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists |
| CA2561755A1 (en) | 2004-04-01 | 2005-10-13 | Warner-Lambert Company Llc | Preparation of p-chirogenic phospholanes and their use in asymmetric synthesis |
| WO2005097799A1 (en) | 2004-04-07 | 2005-10-20 | Pfizer Limited | Pyrazolo`4,3-d! pyrimidines |
| UA82292C2 (uk) | 2004-04-14 | 2008-03-25 | Пфайзер Продактс Инк. | Спосіб стереоселективного біоперетворення аліфатичних динітрилів в ціанокарбонові кислоти (варіанти) |
| US20090170897A1 (en) | 2004-04-20 | 2009-07-02 | Pfizer, Inc. | Method of Treating Neuropathic Pain |
| CN1946391A (zh) | 2004-04-20 | 2007-04-11 | 辉瑞产品公司 | 包含α－2－δ配体的组合 |
| WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| EP1745029A1 (en) | 2004-04-30 | 2007-01-24 | Warner-Lambert Company LLC | Substituted morpholine compounds for the treatment of central nervous system disorders |
| EP1758891A2 (en) | 2004-06-15 | 2007-03-07 | Pfizer Japan Inc. | Benzimidazolone carboxylic acid derivatives |
| US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| EA015418B1 (ru) | 2004-06-21 | 2011-08-30 | УОРНЕР-ЛАМБЕРТ КОМПАНИ ЭлЭлСи | Получение прегабалина и родственных соединений |
| BRPI0512781A (pt) | 2004-06-29 | 2008-04-08 | Pfizer Prod Inc | método para preparação de derivados de 5-{4-(2-hidroxi-propil)-3,5-dioxo-4,5-diidro-3h-[1,2,4]tria zin-2-il}-benzamida através da desproteção dos precursores de protetores de hidroxila |
| US20060003344A1 (en) | 2004-06-30 | 2006-01-05 | Pfizer Inc. | Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40 |
| WO2006008640A1 (en) | 2004-07-15 | 2006-01-26 | Pharmacia & Upjohn Company Llc | Non-aqueous suspension containing a drug having an unpleasant taste |
| JP4056081B1 (ja) | 2004-07-23 | 2008-03-05 | ファイザー・インク | ピリジン誘導体 |
| GB0419849D0 (en) | 2004-09-07 | 2004-10-13 | Pfizer Ltd | Pharmaceutical combination |
| MX2007005290A (es) | 2004-11-02 | 2007-07-09 | Pfizer | Derivados de sulfonilbencimidazol. |
| CN101087771A (zh) | 2004-11-10 | 2007-12-12 | 辉瑞大药厂 | 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物 |
| US7122683B2 (en) | 2004-11-23 | 2006-10-17 | Pfizer Inc. | Amides useful as monoamine re-uptake inhibitors |
| BRPI0518693A2 (pt) | 2004-11-29 | 2008-12-02 | Warner Lambert Co | pirazol [3,4-b]piridinas e indazàis terapÊuticos, bem como composiÇço farmacÊutica e uso dos mesmos |
| BRPI0607456A2 (pt) | 2005-02-22 | 2009-09-08 | Pfizer | derivados de oxindol como agonistas do receptor 5ht4 |
| WO2006092692A1 (en) | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
| CA2600409C (en) | 2005-03-10 | 2011-07-05 | Pfizer Inc. | Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds |
| BRPI0608436A2 (pt) | 2005-03-17 | 2009-12-29 | Pfizer | derivados de n-(n-sulfonilaminometil) ciclopropanocarboxamida utilizáveis para o tratamento de dor |
| JP2008536910A (ja) | 2005-04-20 | 2008-09-11 | ファイザー・リミテッド | プロゲステロン受容体アンタゴニストとしてのピラゾール誘導体 |
| AU2006238933B2 (en) | 2005-04-28 | 2011-12-01 | Pfizer Limited | Amino acid derivatives |
| EP1940380A2 (en) | 2005-05-20 | 2008-07-09 | Pfizer Limited | Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-2 delta-ligands |
| ATE552246T1 (de) | 2005-05-31 | 2012-04-15 | Pfizer | Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten |
| NL2000281C2 (nl) | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
| NL2000284C2 (nl) | 2005-11-04 | 2007-09-28 | Pfizer Ltd | Pyrazine-derivaten. |
| BRPI0618630A2 (pt) | 2005-11-08 | 2011-09-06 | Pfizer Ltd | compostos úteis em terapia, formulação farmacêutica que os contém, e seus usos |
| MEP0408A (xx) | 2005-12-02 | 2010-02-10 | Pfizer Ltd | Derivati hinociklicnog hinazolina kao inhibitori pde7 |
| CA2530904C (en) | 2005-12-20 | 2013-10-08 | John Marino | Pharmaceutical agents for the treatment of pain associated with spinal cord injury |
| RU2008135907A (ru) | 2006-03-06 | 2010-04-20 | Пфайзер Продактс Инк. (Us) | Альфа-2-дельта лиганды для невосстановительного сна |
| GB0700786D0 (en) | 2007-01-15 | 2007-02-21 | Pfizer Ltd | Morpholine dopamine agonists for the treatment of pain |
| EA016494B1 (ru) | 2007-02-02 | 2012-05-30 | Пфайзер Продактс Инк. | (2R,4αS,10αR)-4α-БЕНЗИЛ-7-((2-МЕТИЛПИРИДИН-3-ИЛ)КАРБАМОИЛ)-2-(ТРИФТОРМЕТИЛ)-1,2,3,4,4α,9,10,10α-ОКТАГИДРОФЕНАНТРЕН-2-ИЛДИГИДРОФОСФАТ ИЛИ ЕГО СОЛЬ |
| WO2008132589A1 (en) | 2007-05-01 | 2008-11-06 | Pfizer Limited | Combinations comprising pregabalin |
-
1997
- 1997-07-16 US US09/043,358 patent/US6001876A/en not_active Expired - Lifetime
- 1997-07-16 JP JP50706298A patent/JP3693258B2/ja not_active Expired - Lifetime
- 1997-07-16 ES ES97932617.0T patent/ES2200184T7/es active Active
- 1997-07-16 BR BR9710536A patent/BR9710536A/pt not_active Application Discontinuation
- 1997-07-16 NZ NZ332762A patent/NZ332762A/xx not_active IP Right Cessation
- 1997-07-16 AT AT97932617T patent/ATE241351T1/de active
- 1997-07-16 PT PT97932617T patent/PT934061E/pt unknown
- 1997-07-16 SI SI9730545T patent/SI0934061T1/xx unknown
- 1997-07-16 EP EP97932617.0A patent/EP0934061B3/en not_active Expired - Lifetime
- 1997-07-16 DK DK97932617.0T patent/DK0934061T6/en active
- 1997-07-16 US US11/983,750 patent/USRE41920E1/en not_active Expired - Lifetime
- 1997-07-16 CN CN97196041A patent/CN1094757C/zh not_active Expired - Lifetime
- 1997-07-16 CA CA002255652A patent/CA2255652C/en not_active Expired - Lifetime
- 1997-07-16 AU AU36024/97A patent/AU714980B2/en not_active Expired
- 1997-07-16 KR KR10-1999-7000577A patent/KR100491282B1/ko active IP Right Review Request
- 1997-07-16 IL IL12699997A patent/IL126999A/en not_active IP Right Cessation
- 1997-07-16 DE DE1997622426 patent/DE69722426T3/de not_active Expired - Lifetime
- 1997-07-16 WO PCT/US1997/012390 patent/WO1998003167A1/en active IP Right Grant
- 1997-07-16 PL PL97331325A patent/PL189872B1/pl unknown
- 1997-07-16 HU HU9904361A patent/HU228426B1/hu active Protection Beyond IP Right Term
- 1997-07-17 HR HR60/022,337A patent/HRP970387A2/hr not_active Application Discontinuation
- 1997-07-23 ZA ZA9706562A patent/ZA976562B/xx unknown
-
1999
- 1999-01-22 NO NO19990279A patent/NO325822B1/no not_active IP Right Cessation
- 1999-01-22 CU CU1999008A patent/CU22850A3/es unknown
- 1999-12-09 HK HK99105747A patent/HK1021134A1/xx not_active IP Right Cessation
-
2008
- 2008-12-04 NO NO2008018C patent/NO2008018I2/no unknown
-
2013
- 2013-08-27 HU HUS1300046C patent/HUS1300046I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP970387A2 (en) | Isobutylgaba and its derivatives for the treatment of pain | |
| JP6076737B2 (ja) | 高血圧症の防止及び治療のための組成物並びに方法 | |
| US20090162421A1 (en) | Drugs as well as their production and use in the treatment of pain-associated neuropathies | |
| JP2016175926A (ja) | 神経変性および神経炎症の治療 | |
| WO2008060572A1 (en) | Use of gabapentin and pregabalin prodrugs for treating tinnitus | |
| US20090076141A1 (en) | Use of Propofol Prodrugs for Treating Neuropathic Pain | |
| US20090005444A1 (en) | Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus | |
| Anand et al. | Sustained inhibition of brotizolam induced anterograde amnesia by norharmane and retrograde amnesia by l-glutamic acid in mice | |
| JP6411893B2 (ja) | （ｓ）２−ｎ（３−ｏ−（プロパン２−オール）−１−プロピル−４−ヒドロキシベンゼン）−３−フェニルプロピルアミドの単離された立体異性体型 | |
| EP3818981A1 (en) | Synergic pharmaceutical composition of the active enantiomer (s)-ketorolac and gabapentin for the treatment of neuropathic pain | |
| CN113181174A (zh) | Bl-1249在制备治疗神经病理性疼痛的药物中的应用 | |
| JP6461961B2 (ja) | ジエチル（２−シアノエチル）ホスホネートの医薬組成物および使用 | |
| JP6360163B2 (ja) | ３，４−ビス−ベンジルスルホニルブタンニトリル及びその医薬上の使用 | |
| Simler et al. | Anticonvulsant and antiaggressive properties of di-n-propyl acetate after repeated treatment | |
| Eldor | Intralipid Infusion for Myelin Sheath Repair in Multiple Sclerosis and Trigeminal Neuralgia | |
| US20080139651A1 (en) | Compounds useful for treating neurological disorders | |
| CN117530940A (zh) | α-酮戊二酸在制备促髓鞘修复、改善神经炎症的药物中的应用 | |
| JP2005513101A (ja) | 慢性疼痛の治療のための２−インダニルアミノ誘導体 | |
| JP2016531878A (ja) | ３−ベンジルスルホニルプロピオニトリルの医薬上の使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODBI | Application refused |